Should I buy or sell Scilex stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCLX shares. View SCLX analyst ratings or view top-rated stocks .

What is Scilex's stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Scilex's shares. Their SCLX share price targets range from $4.00 to $12.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price. View analysts price targets for SCLX or view top-rated stocks among Wall Street analysts .

How have SCLX shares performed in 2023?

Scilex's stock was trading at $3.99 at the beginning of the year. Since then, SCLX stock has decreased by 48.9% and is now trading at $2.04. View the best growth stocks for 2023 here .

When is Scilex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our SCLX earnings forecast .

How were Scilex's earnings last quarter?

Scilex Holding (NASDAQ:SCLX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.46. The company had revenue of $10.12 million for the quarter, compared to the consensus estimate of $12.26 million. Scilex had a negative net margin of 245.17% and a negative trailing twelve-month return on equity of 437.77%.

What ETFs hold Scilex's stock?

ETFs with the largest weight of Scilex (NASDAQ:SCLX) stock in their portfolio include Morningstar US Small Growth (MSGR) , ETFMG Treatments Testing and Advancements ETF (GERM) , Global X Genomics & Biotechnology ETF (GNOM) and Invesco PureBeta MSCI USA Small Cap ETF (PBSM) . Nationwide Russell 2000 Risk Managed Income ETF (NTKI) .

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:SCLX

Scilex (SCLX) Stock Price, News & Analysis

$2.04

+0.20 (+10.87%)

(As of 12/29/2023 ET)

Compare

Today's Range: $1.81
▼
$2.08
50-Day Range: $0.95
▼
$2.04
52-Week Range: $0.90
▼
$16.90

Volume: 1.13 million shs
Average Volume: 855,351 shs
Market Capitalization: $322.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Scilex MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 292.2% Upside
$8.00 Price Target
Short Interest: Bearish
5.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.57) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

497th out of 950 stocks

Biological Products, Except Diagnostic Industry

90th out of 158 stocks

3.5

Analyst's Opinion

Consensus Rating
Scilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Scilex has a forecasted upside of 292.2% from its current price of $2.04.
Amount of Analyst Coverage
Scilex has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.32% of the float of Scilex has been sold short.
Short Interest Ratio / Days to Cover
Scilex has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Scilex has recently decreased by 2.16%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Scilex does not currently pay a dividend.
Dividend Growth
Scilex does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SCLX.

3.8

News and Social Media Coverage

News Sentiment
Scilex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Scilex this week, compared to 1 article on an average week.
Search Interest
15 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.
MarketBeat Follows
5 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Scilex insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.40% of the stock of Scilex is held by insiders.
Percentage Held by Institutions
78.20% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Scilex are expected to grow in the coming year, from ($1.00) to ($0.57) per share.
Price to Book Value per Share Ratio
Scilex has a P/B Ratio of 7.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Scilex Stock (NASDAQ:SCLX)

Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

SCLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SCLX Stock News Headlines

December 21, 2023 | seekingalpha.com

SCLXW Scilex Holding Company WT EXP 111027

December 15, 2023 | msn.com

Scilex Announces Partner to Stock its Products

December 31, 2023 | Behind the Markets (Ad)

FINAL OFFER: $9 for a FULL YEAR of stock picks

We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?

December 15, 2023 | finance.yahoo.com

Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.

December 13, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Scilex Holding Amid Market Access Expansion and Positive Clinical Results

December 12, 2023 | finance.yahoo.com

Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population

December 6, 2023 | finance.yahoo.com

Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State

December 5, 2023 | markets.businessinsider.com

Strategic Advancements and Financial Growth Affirm Buy Rating for Scilex Holding Company

December 31, 2023 | Behind the Markets (Ad)

FINAL OFFER: $9 for a FULL YEAR of stock picks

We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?

December 4, 2023 | finance.yahoo.com

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee

December 1, 2023 | finance.yahoo.com

Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information

November 28, 2023 | finance.yahoo.com

Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.

November 21, 2023 | finance.yahoo.com

Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®

November 18, 2023 | morningstar.com

Scilex Holding Co SCLX

November 17, 2023 | benzinga.com

Thinking about buying stock in Alibaba Group, Uber, Walt Disney Co, ChargePoint Holdings, or Scilex Holding?

November 17, 2023 | finance.yahoo.com

Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch

November 15, 2023 | msn.com

Scilex announces issuance of new patent for its lead commercial product ZTlido

November 15, 2023 | msn.com

SCLX Provides non-Opioid Pain Relief

November 15, 2023 | finance.yahoo.com

Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch

November 7, 2023 | markets.businessinsider.com

Analysts’ Top Consumer Goods Picks: Scilex Holding Company (SCLX), Walmart (WMT)

November 2, 2023 | finance.yahoo.com

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

November 2, 2023 | finance.yahoo.com

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

November 1, 2023 | finance.yahoo.com

Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information

October 27, 2023 | finance.yahoo.com

Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

October 27, 2023 | finance.yahoo.com

UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure

October 26, 2023 | finance.yahoo.com

SCLX: An Innovative and Growing Pain Management Company

October 14, 2023 | msn.com

B. Riley Securities Initiates Coverage of Scilex Holding (SCLX) with Buy Recommendation

See More Headlines

Receive SCLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SCLX
CUSIP: N/A
CIK: 1820190
Web: www.scilexholding.com
Phone: 650-516-4310
Fax: N/A
Employees: 109
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $12.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +292.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,360,000.00
Net Margins: -245.17%
Pretax Margin: -245.07%
Return on Equity: -437.77%
Return on Assets: -112.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.11
Quick Ratio: 0.09

Sales & Book Value

Annual Sales: $45.20 million
Price / Sales: 7.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.26 per share
Price / Book: 7.85

Miscellaneous

Outstanding Shares: 157,906,000
Free Float: 144,642,000
Market Cap: $322.13 million
Optionable: Not Optionable
Beta: 0.32

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Henry H. Ji Ph.D. (Age 59)
Executive Chairman
Comp: $4.35M
Mr. Jaisim Shah (Age 63)
President, CEO & Director
Comp: $785.73k
Mr. Stephen Ma (Age 51)
Senior VP & CFO
Dr. Suketu D. Desai Ph.D. (Age 57)
Chief Technical Officer & Senior VP
Mr. Steven F. Lincoln J.D.
General Counsel & Chief Compliance Officer
Mr. Suresh K. Khemani (Age 63)
Senior VP & Chief Commercial Officer
Comp: $456.82k
Dr. Dmitri V. Lissin M.D. (Age 63)
Senior VP & Chief Medical Officer
Comp: $528.83k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SCLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Scilex stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCLX shares.
View SCLX analyst ratings or view top-rated stocks.
What is Scilex's stock price target for 2024?: 2 equities research analysts have issued 1 year target prices for Scilex's shares. Their SCLX share price targets range from $4.00 to $12.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price.
View analysts price targets for SCLX or view top-rated stocks among Wall Street analysts.
How have SCLX shares performed in 2023?: Scilex's stock was trading at $3.99 at the beginning of the year. Since then, SCLX stock has decreased by 48.9% and is now trading at $2.04.
View the best growth stocks for 2023 here.
When is Scilex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our SCLX earnings forecast.

How were Scilex's earnings last quarter?: Scilex Holding (NASDAQ:SCLX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.46. The company had revenue of $10.12 million for the quarter, compared to the consensus estimate of $12.26 million. Scilex had a negative net margin of 245.17% and a negative trailing twelve-month return on equity of 437.77%.
What ETFs hold Scilex's stock?: ETFs with the largest weight of Scilex (NASDAQ:SCLX) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM) and Invesco PureBeta MSCI USA Small Cap ETF (PBSM).Nationwide Russell 2000 Risk Managed Income ETF (NTKI).
How do I buy shares of Scilex?: Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCLX) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial